{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:42:17Z","timestamp":1785552137350,"version":"3.56.0"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100017962","name":"Jiangsu Provincial Health Commission","doi-asserted-by":"publisher","award":["ZD2021035"],"award-info":[{"award-number":["ZD2021035"]}],"id":[{"id":"10.13039\/100017962","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The mechanism of livedoid vasculopathy (LV) remains unknown.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To investigate the association between coagulation factors and LV and to assess the efficacy and safety of rivaroxaban in the treatment of patients with LV.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>From May 2019 to July 2022, 89 patients with LV and 35 healthy controls were included in a cross-sectional cohort to measure the levels of coagulation factors. In addition, 55 patients with LV treated with rivaroxaban were included in a treatment cohort to assess the complete remission rate of ulcers (n = 44) and retiform purpura (n = 11) within 12 weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In the cross-sectional cohort, the activities of coagulation factor X in patients with LV were significantly higher than those in healthy controls: median 110.5% [interquartile range (IQR) 97.5\u2013127.0%] vs. 101.3% (IQR 91.6\u2013115.6); P = 0.05. In addition, coagulation factor X activities in the progressive stage were higher than at the stable stage: median 111.6% (IQR 102.3\u2013132.5) vs. 105.4% (IQR 92.9\u2013118.8); P = 0.04. Moreover, coagulation factor X activities were higher at the progressive stage than at the stable stage in a subgroup of 20 patients with LV (P = 0.04). In the treatment cohort taking rivaroxaban, 91% (40\/44) of patients with ulcers achieved complete remission within 12 weeks, and 73% (8\/11) of patients with retiform purpura achieved complete remission within 12 weeks. Mild side-effects occurred in 25% of patients (14\/55), including menorrhagia (n = 10), gingival bleeding (n = 3) and haemorrhage (n = 1).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Coagulation factor X was associated with the incidence and severity of LV in this study. In addition, rivaroxaban was an effective and safe treatment for ulcers and retiform purpura in people with LV.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ced\/llae023","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T06:40:26Z","timestamp":1706596826000},"page":"817-824","source":"Crossref","is-referenced-by-count":7,"title":["Associations between coagulation factors and livedoid vasculopathy and the efficacy and safety of rivaroxaban in patients with livedoid vasculopathy: a retrospective study"],"prefix":"10.1093","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3084-4891","authenticated-orcid":false,"given":"Chenjing","family":"Zhao","sequence":"first","affiliation":[{"name":"Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College , Nanjing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiwen","family":"Yu","sequence":"additional","affiliation":[{"name":"Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College , Nanjing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianfeng","family":"Cheng","sequence":"additional","affiliation":[{"name":"Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College , Nanjing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suo","family":"Li","sequence":"additional","affiliation":[{"name":"Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College , Nanjing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suying","family":"Feng","sequence":"additional","affiliation":[{"name":"Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College , Nanjing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,30]]},"reference":[{"key":"2024071909345069100_llae023-B1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s001050050243","article-title":"Livedo vasculitis","volume":"46","author":"Fritsch","year":"1995","journal-title":"Hautarzt"},{"key":"2024071909345069100_llae023-B2","doi-asserted-by":"crossref","first-page":"574","DOI":"10.2340\/00015555-1711","article-title":"Livedoid vasculopathy: clinical features and treatment in 24 Chinese patients","volume":"94","author":"Feng","year":"2014","journal-title":"Acta Derm Venereol"},{"key":"2024071909345069100_llae023-B3","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/ijd.16477","article-title":"Clinical analysis of skin lesions in livedoid vasculopathy: a study of 46 Chinese patients","volume":"62","author":"Zhao","year":"2023","journal-title":"Int J Dermatol"},{"key":"2024071909345069100_llae023-B4","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1365-2133.2011.10216.x","article-title":"Livedoid vasculopathy secondary to high levels of lipoprotein(a)","volume":"164","author":"Vasconcelos","year":"2011","journal-title":"Br J Dermatol"},{"key":"2024071909345069100_llae023-B5","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1111\/iwj.13480","article-title":"Plasminogen activator inhibitor-1: a potential etiological role in livedoid vasculopathy","volume":"17","author":"Gao","year":"2020","journal-title":"Int Wound J"},{"key":"2024071909345069100_llae023-B6","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1111\/jdv.15639","article-title":"Characteristics, risk factors and treatment reality in livedoid vasculopathy \u2013 a multicentre analysis","volume":"33","author":"Weishaupt","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024071909345069100_llae023-B7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1053\/j.seminhematol.2007.01.006","article-title":"Plasma coagulation factor levels in venous thrombosis","volume":"44","author":"Nossent","year":"2007","journal-title":"Semin Hematol"},{"key":"2024071909345069100_llae023-B8","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1111\/jdv.16129","article-title":"Livedoid vasculopathy in Koreans: clinical features and response to rivaroxaban treatment","volume":"34","author":"Lee","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024071909345069100_llae023-B9","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/ijd.13997","article-title":"The management of livedoid vasculopathy focused on direct oral anticoagulants (DOACs): four case reports successfully treated with rivaroxaban","volume":"57","author":"Franco Marques","year":"2018","journal-title":"Int J Dermatol"},{"key":"2024071909345069100_llae023-B10","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1016\/S2352-3026(15)00251-3","article-title":"Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial","volume":"3","author":"Weishaupt","year":"2016","journal-title":"Lancet Haematol"},{"key":"2024071909345069100_llae023-B11","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1684\/ejd.2019.3554","article-title":"Livedoid vasculopathy: does hyperhomocysteinaemia play an aetiological role?","volume":"29","author":"Marsch","year":"2019","journal-title":"Eur J Dermatol"},{"key":"2024071909345069100_llae023-B12","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1046\/j.1365-2133.2000.03786.x","article-title":"Livedoid vasculopathy associated with heterozygous protein C deficiency","volume":"143","author":"Boyvat","year":"2000","journal-title":"Br J Dermatol"},{"key":"2024071909345069100_llae023-B13","doi-asserted-by":"crossref","first-page":"478","DOI":"10.4103\/0378-6323.183635","article-title":"Livedoid vasculopathy: a\u00a0review of pathogenesis and principles of management","volume":"82","author":"Vasudevan","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae023\/57242689\/llae023.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/8\/817\/58594144\/llae023.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/8\/817\/58594144\/llae023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T09:35:06Z","timestamp":1721381706000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/49\/8\/817\/7591596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,30]]},"references-count":13,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,1,30]]},"published-print":{"date-parts":[[2024,7,19]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae023","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,1,30]]}}}